G1 Therapeutics, Inc.
G1 Therapeutics is dedicated to developing and delivering next-generation cancer therapies aimed at improving the lives and outcomes of people living with cancer. As a subsidiary of Pharmacosmos Therapeutics, the company focuses on innovative treatments, including Trilaciclib, to address chemotherapy-induced myelosuppression and enhance immune responses in cancer patients.
Industries
Nr. of Employees
medium (51-250)
G1 Therapeutics, Inc.
Not specified in the provided content
Products
Intravenous CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression
An intravenously administered CDK4/6 inhibitor given prior to cytotoxic chemotherapy to reduce multilineage myelosuppression, preserve immune function, and decrease the need for supportive-care interventions.
Intravenous CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression
An intravenously administered CDK4/6 inhibitor given prior to cytotoxic chemotherapy to reduce multilineage myelosuppression, preserve immune function, and decrease the need for supportive-care interventions.
Services
Design and conduct of Phase I–III clinical trials, translational studies, real-world evidence projects, and HEOR analyses to support therapeutic development.
Design and conduct of Phase I–III clinical trials, translational studies, real-world evidence projects, and HEOR analyses to support therapeutic development.
Expertise Areas
- Oncology clinical trial management
- Myeloprotection strategies for chemotherapy
- Immuno-oncology translational research
- Pharmacokinetics and pharmacodynamics
Key Technologies
- CDK4/6-targeted kinase inhibition
- Preclinical tumor models
- T-cell and tumor immune profiling assays
- PK/PD modeling and analysis